NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
PMV Pharma's financial performance for Q3 2023 was reported, highlighting clinical trial updates and financial results.
PMV Pharma reported its Q3 2023 financial results, featuring updated Phase 1 data from the PYNNACLE clinical trial, demonstrating efficacy and safety of PC14586. The company ended the quarter with $238.1 million in cash, cash equivalents, and marketable securities.
- Updated Phase 1 PYNNACLE trial data showed responses across multiple tumor types with a median duration of response of seven months.
- An overall response rate of 38% was observed at the recommended Phase 2 dose for TP53 Y220C and KRAS wild-type patients.
- A registrational Phase 2 clinical trial is expected to start in Q1 2024.
- Enrollment is ongoing in the combination arm of the PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab).
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
PMV Pharma plans to initiate a registrational tumor-agnostic Phase 2 clinical trial in early 2024 and continues to enroll patients in the combination arm of PYNNACLE evaluating PC14586 with KEYTRUDA®.
Tailwinds
- Initiate a registrational tumor-agnostic Phase 2 clinical trial in early 2024.
- Enrollment ongoing in PYNNACLE combination arm.
- PMV and Merck collaboration continues.
- FDA granted Fast Track designation to PC14586.
- Clinical efficacy and safety of PC14586 demonstrated.
Headwinds
- Success of clinical trials is uncertain.
- Clinical trials may differ from expected results.
- Company's ability to fund operations is a risk.
- COVID-19 pandemic may impact clinical trials.
- Regulatory approval is not guaranteed.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro